Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SOPHiA GENETICS SASOPH · Entity 5228 | Chief Legal Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SOPHiA GENETICS SA
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 332,716 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Sale · Disposed 6,168 · Balance 332,716 F1: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on October 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.91 to $8.30, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on October 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.91 to $8.30, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 7, 2026 20:04 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 6,168 | $8.12 | $50,100.20 |
DisclosureSEC source: 0001840706-26-000336 · wk-form4_1791403479.xml · nonDerivative · entry 1 Van Well Daan · CIK 0002006414 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 332,716 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on October 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.91 to $8.30, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 11, 2026 Filed Sep 14, 2026 20:01 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 6,168 | $7.63 | $47,088.98 |
DisclosureSEC source: 0001840706-26-000310 · wk-form4_1789416108.xml · nonDerivative · entry 1 Van Well Daan · CIK 0002006414 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 338,884 F1 · shares: Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.55 to $7.85, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:02 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 684 | $4.60 | $3,149.27 |
DisclosureSEC source: 0001840706-26-000197 · wk-form4_1779307352.xml · nonDerivative · entry 1 Van Well Daan · CIK 0002006414 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 345,052 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on May 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.54 to $4.66, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 20:04 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 684 | $5.20 | $3,554.27 |
DisclosureSEC source: 0001840706-26-000172 · wk-form4_1776801876.xml · nonDerivative · entry 1 Van Well Daan · CIK 0002006414 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 345,736 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.10 to $5.29, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 10, 2026 Filed Apr 14, 2026 20:02 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 2,400 | $4.67 | $11,201.28 |
DisclosureSEC source: 0001840706-26-000152 · wk-form4_1776196932.xml · nonDerivative · entry 1 Van Well Daan · CIK 0002006414 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 346,420 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.61 to $4.77, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 20:02 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 1,988 | $4.74 | $9,424.31 |
DisclosureSEC source: 0001840706-26-000137 · wk-form4_1775851332.xml · nonDerivative · entry 2 Van Well Daan · CIK 0002006414 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 348,820 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. F3 · balance_after: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.61 to $4.86, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 20:02 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 2,861 | $4.85 | $13,862.12 |
DisclosureSEC source: 0001840706-26-000137 · wk-form4_1775851332.xml · nonDerivative · entry 1 Van Well Daan · CIK 0002006414 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 350,808 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.78 to $4.94, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:04 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 2,400 | $4.87 | $11,681.76 |
DisclosureSEC source: 0001840706-26-000126 · wk-form4_1775678693.xml · nonDerivative · entry 2 Van Well Daan · CIK 0002006414 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 353,669 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.77 to $4.945, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:04 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 2,705 | $4.86 | $13,136.02 |
DisclosureSEC source: 0001840706-26-000126 · wk-form4_1775678693.xml · nonDerivative · entry 1 Van Well Daan · CIK 0002006414 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 356,069 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.685 to $4.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 10:58 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | GrantShare Option (Right to Buy) · Derivative | 142,216 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001840706-26-000084 · wk-form4_1775213927.xml · derivative · entry 2 Van Well Daan · CIK 0002006414 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,216 Underlying: Ordinary Shares · 142,216 shares Expires 2036-04-02 F2 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 10:58 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | GrantOrdinary Shares | 97,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001840706-26-000084 · wk-form4_1775213927.xml · nonDerivative · entry 1 Van Well Daan · CIK 0002006414 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,536 F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. Read SEC document |
| April 02, 2026 Filed Apr 8, 2026 12:47 UTC Amendment | SOPHiA GENETICS SA SOPH · Entity 5228 | GrantShare Option (Right to Buy) · Derivative | 142,216 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001840706-26-000110 · wk-form4a_1775652449.xml · derivative · entry 2 Van Well Daan · CIK 0002006414 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,216 Underlying: Ordinary Shares · 142,216 shares Expires 2036-04-02 F3 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030. Read SEC document |
| April 02, 2026 Filed Apr 8, 2026 12:47 UTC Amendment | SOPHiA GENETICS SA SOPH · Entity 5228 | GrantOrdinary Shares | 97,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001840706-26-000110 · wk-form4a_1775652449.xml · nonDerivative · entry 1 Van Well Daan · CIK 0002006414 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,774 F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. F2 · balance_after: This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 97,536 ordinary shares due to an inadvertent error. The correct amount is 358,774 ordinary shares. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:01 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 684 | $4.79 | $3,273.97 |
DisclosureSEC source: 0001840706-26-000071 · wk-form4_1774036905.xml · nonDerivative · entry 1 Van Well Daan · CIK 0002006414 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 261,238 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on March 18, 2026. The sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.69 to $4.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.